At a glance
ClinicalIndex Comparison RecordN/ACompleted· 25 enrolled
Drug / intervention
RD19device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Open-label, First-in-Man Acute Safety, Tolerability and Device Acceptability Study of Experimental Device RD19 for Protection From Human Respiratory Tract Pathogens
In Brief
A clinical study evaluating RD19 for Respiratory Tract Infections. Completed, enrolled 25 participants across 1 site.
Detailed Summary
This first-in-man (FIM) phase I study will evaluate the acute safety, tolerability, and acceptability of the investigational RD19 device among 25 healthy volunteers between the age of 18 and 45.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRespiratory Tract Infections
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartAug 2020
First PostedSep 2020
Primary CompletionSep 2020
Study CompletionDec 2020
TodayJul 2026
First PostedSep 22, 2020
Enrollment StartAug 31, 2020
Primary CompletionSep 23, 2020
Study CompletionDec 7, 2020
TodayJul 2, 2026
Enrollment to primary: 22 daysPosted 5.8 years ago
Interventions
RD19device
Experimental device that uses safe electromagnetic energy to stimulate the proximal repository of respiratory tract infectious disease pathogens